Pipeline
In Summer 2010 Etubics entered into Phase I Clinical Trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen (CEA)-expressing cancers such as colorectal cancer. Plans are underway to initiate clinical trials for a therapeutic breast cancer vaccine and a preventative influenza vaccine in 2011. Etubics continues to move forward on its pre clinical activities for vaccines for HIV, malaria and other difficult to treat diseases.
